Results 241 to 250 of about 2,694,794 (307)

At the boundary: Law and AI. [PDF]

Proc Natl Acad Sci U S A
Ho DE, Nyarko J, Parli V, Manning CD.
europepmc   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres, Cristobalina Mayorga, Elizabeth J. Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Mariana Castells, Gülfem Çelik, Knut Brockow, Lene H. Garvey, Inmaculada Doña, Jean‐Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H. Li, Vito Sabato   +19 more
wiley   +1 more source

Continuity and change in US legal tradition: Evidence from judicial citation communities. [PDF]

Proc Natl Acad Sci U S A
Ash E, Chiopris C, Mahari R, Naidu S.
europepmc   +1 more source

Stability of potato glycoalkaloids under heating conditions - Reactions with fatty acids. [PDF]

Curr Res Food Sci
Mittau K, Meyers C, Rawel HM, Smit I, Schmidt M, Rohn S.   +5 more
europepmc   +1 more source

Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial

British Journal of Haematology, EarlyView.
Elevated percentage of immature platelets is indicative of consumptive thrombocytopenic disorders. In immune thrombocytopenia, low platelet counts may result from reduced production or increased degradation, both driven by IgG autoantibodies. By blocking FcRn, efgartigimod decreases immature platelet fraction, likely by reducing platelet degradation ...
Hanny Al‐Samkari, Filip Matthijssens, Kaichi Nishiwaki, Francesco Zaja, Sylvian Audia, Yoshitaka Miyakawa, Jaume Ayguasanosa, Damien Chimits, Anna Hultberg, Peter Ulrichts   +9 more
wiley   +1 more source

Childhood-Onset Takayasu Arteritis With Extensive Vascular Involvement: A Four-Decade Follow-Up Case Report. [PDF]

Case Rep Rheumatol
Djumaeva N, Achundjanova G, Djumaeva L.
europepmc   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source

Challenges in diagnosing malignant lymphoma involving the spine: illustrative cases. [PDF]

J Neurosurg Case Lessons
Farhan MR, Sangatsuda Y, Ito A, Takahashi Y, Saito M, Nishimura S, Fujita K, Ichikawa S, Sasaki T, Faried A, Endo T.   +10 more
europepmc   +1 more source

Unsupervised Deep Representation Learning and Probabilistic Clustering for the Systems-Level Discovery of Germline Mutation Signatures in Pediatric Cancers. [PDF]

Biomedicines
Palizban F, March ME, Wang X, Snyder J, Wang F, Mentch F, Mahesh Y, Thomas A, Watson DJ, Qu H, Connolly J, Saeidian AH, Vahidnezhad H, Glessner J, Hakonarson H.   +14 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source